Research programme: skin disorder therapies - Antares/Dr Reddy's
Latest Information Update: 26 May 2022
At a glance
- Originator Antares Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Skin disorders
Most Recent Events
- 24 May 2022 Antares Pharma has been acquired by Halozyme Therapeutics
- 03 Sep 2008 Preclinical trials in Skin disorders in USA (Topical)